Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Following after is P-500, a selective, brain-penetrant PRMT5 inhibitor for advanced solid tumours, including high-grade ...

During a live event, Xiuning Le, MD, PhD, discussed clinical trials of supportive care for infusion reaction and skin rash ...

Novo Nordisk announced it will work with the biotech Septerna to develop oral GLP-1 obesity drugs in a deal worth up to $2.2 ...

While many pharma and biotech companies developing drugs to treat Alzheimer's disease are targeting amyloid beta plaque, Eli ...

Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent ...

The U.S. FDA granted Abbvie Inc. accelerated approval for antibody-drug conjugate (ADC) Teliso-V (telisotuzumab vedotin), newly branded Emrelis, making it the first treatment for previously treated ...

The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult ...

Growth stocks, particularly those in the biotech sector, can be lucrative long-term investments. The biotech sector often ...

Molecular-guided decision-making improves disease control and remission in the treatment of IBD with anti-TNF therapy, however, application to other therapies is questioned.

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a ...

Eli Lilly and Purdue University expand their partnership with a $250 million investment to advance pharmaceutical innovation ...